Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus CIPRO HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus CIPRO HC.
CHLORAMPHENICOL SODIUM SUCCINATE vs CIPRO HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S ribosomal subunit, inhibiting peptidyl transferase activity and blocking protein synthesis in bacteria.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
Intravenous, 50 mg/kg/day divided every 6 hours; maximum 4 g/day.
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3.5 hours in adults with normal renal and hepatic function. In neonates (first 2 weeks of life), half-life is prolonged to 10-24 hours due to immature hepatic conjugation. In patients with severe hepatic impairment, half-life may exceed 12 hours, necessitating dose adjustment.
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
Approximately 80-90% of the dose is excreted renally as unchanged drug and as the inactive chloramphenicol base (formed by hydrolysis in the liver and kidneys). Biliary excretion accounts for about 5-10%, with some enterohepatic circulation. Fecal excretion is negligible (<2%).
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Category D/X
Category C
Antibiotic
Antibiotic/Corticosteroid Combination (Otic)